Lu Jing, Tang Xiaolei, Zhang Yuxin, Chu Hongbo, Jing Chenxu, Wang Yufeng, Lou Huijuan, Zhu Ziqi, Zhao Daqing, Sun Liwei, Cong Deyu
Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Jilin, China.
Department of Tuina, The Affiliated Hospital to Changchun University of Chinese Medicine, Jilin, China.
Heliyon. 2023 Dec 16;10(1):e23742. doi: 10.1016/j.heliyon.2023.e23742. eCollection 2024 Jan 15.
BACKGROUND: Ischemic stroke (IS) is a leading cause of long-term disability and even mortality, threatening people's lives. Yinao Fujian (YNFJ) formula is a Traditional Chinese Medicine formula that has been widely used to treat patients with IS. However, the molecular mechanism of YNFJ for the treatment of IS is still elusive. Our study aimed to explore the potential protective effect and the underlying mechanisms of YNFJ on IS using a network pharmacology approach coupled with experimental validation. MATERIALS AND METHODS: Effective compounds of YNFJ were collected from BATMAN-TCM and TCMSP databases, while IS targets were obtained from GeneCards, OMIM, TTD and DrugBank databases. The protein-protein interaction (PPI) network was constructed to further screen the hub targets of YNFJ in IS treatment. GO and KEGG enrichment analyses were used to identify the critical biological processes and signaling pathways of YNFJ for IS. Moreover, Nissl staining, HE, TTC staining and Tunel staining were used in the MCAO model to prove the neuroprotective effect of YNFJ. Oxidative damage, inflammatory factor release and related pathways were tested in MCAO rat model and hypoxia-induced BV2 cell model, respectively. RESULTS: We found that YNFJ treatment significantly alleviated MCAO-induced nerve damage and apoptosis. Then, network pharmacology screening combined with literature research revealed IL6, TNF, PTGS2, NFKBIA and NFE2L2 as the critical targets in a PPI network. Moreover, the top 20 signaling pathways and biological processes associated with the protective effects of YNFJ on IS were enriched through GO and KEGG analyses. Further analysis indicated that NF-κB and Nrf2/HO-1 signaling pathways might be highly involved in the protective effects of YNFJ on IS. Finally, and experiments confirmed that YNFJ inhibited the release of inflammatory factors (IL-6 and TNF-α) and MDA content, and increased the activity of SOD. In terms of the mechanism, YNFJ inhibited the release of inflammatory factors by suppressing the NF-κB pathway and decreased the expression of iNOS and COX-2 to protect microglia from inflammation damage. In addition, YNFJ initiated the dissociation of Keap-1 and Nrf2, and activated the downstream protein HO-1, NQO1, thus decreasing oxidative stress. CONCLUSION: Taken together, the findings in our research showed that the protective effects of YNFJ on IS were mainly achieved by regulating the NF-κB and Nrf2/HO-1 signaling pathways to inhibit oxidative stress damage and inflammatory damage of microglia.
背景:缺血性中风(IS)是导致长期残疾甚至死亡的主要原因,威胁着人们的生命。益脑复健(YNFJ)方剂是一种广泛用于治疗IS患者的中药方剂。然而,YNFJ治疗IS的分子机制仍不清楚。我们的研究旨在通过网络药理学方法结合实验验证,探讨YNFJ对IS的潜在保护作用及其潜在机制。 材料与方法:从BATMAN-TCM和TCMSP数据库收集YNFJ的有效成分,从GeneCards、OMIM、TTD和DrugBank数据库获取IS靶点。构建蛋白质-蛋白质相互作用(PPI)网络,以进一步筛选YNFJ在IS治疗中的核心靶点。采用GO和KEGG富集分析来确定YNFJ治疗IS的关键生物学过程和信号通路。此外,在大脑中动脉闭塞(MCAO)模型中使用尼氏染色、苏木精-伊红(HE)染色、TTC染色和Tunel染色来证明YNFJ的神经保护作用。分别在MCAO大鼠模型和缺氧诱导的BV2细胞模型中检测氧化损伤、炎症因子释放及相关通路。 结果:我们发现YNFJ治疗显著减轻了MCAO诱导的神经损伤和细胞凋亡。然后,网络药理学筛选结合文献研究揭示白细胞介素6(IL6)、肿瘤坏死因子(TNF)、前列腺素内过氧化物合酶2(PTGS2)、核因子κB抑制因子α(NFKBIA)和核因子E2相关因子2(NFE2L2)是PPI网络中的关键靶点。此外,通过GO和KEGG分析富集了与YNFJ对IS的保护作用相关的前20条信号通路和生物学过程。进一步分析表明,核因子κB(NF-κB)和核因子E2相关因子2/血红素加氧酶-1(Nrf2/HO-1)信号通路可能高度参与YNFJ对IS的保护作用。最后,实验证实YNFJ抑制炎症因子(IL-6和TNF-α)的释放和丙二醛(MDA)含量,并提高超氧化物歧化酶(SOD)的活性。在机制方面,YNFJ通过抑制NF-κB通路抑制炎症因子的释放,并降低诱导型一氧化氮合酶(iNOS)和环氧化酶-2(COX-2)的表达,以保护小胶质细胞免受炎症损伤。此外,YNFJ引发 Kelch样ECH相关蛋白1(Keap-1)和Nrf2的解离,并激活下游蛋白HO-1、醌氧化还原酶1(NQO1),从而降低氧化应激。 结论:综上所述,我们的研究结果表明,YNFJ对IS的保护作用主要是通过调节NF-κB和Nrf2/HO-1信号通路来抑制小胶质细胞的氧化应激损伤和炎症损伤实现的。
Zhongguo Zhong Yao Za Zhi. 2023-6
Physiology (Bethesda). 2024-9-1
J Cardiovasc Pharmacol. 2021-6-1
Exp Ther Med. 2021-6